Eisai-Site Updates /index.html English News Release,Information,Latest News. A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association Demonstrating the Utility of Blood Biomarkers in Predicting Amyloid Beta Accumulation in the Brain /news/2024/news202477.html Eisai's news release A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association Demonstrating the Utility of Blood Biomarkers in Predicting Amyloid Beta Accumulation in the Brain is posted. 2024-10-17T10:00:00+09:00 UPDATE ON REGULATORY REVIEW OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN AUSTRALIA /news/2024/news202476.html Eisai's news release UPDATE ON REGULATORY REVIEW OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE IN AUSTRALIA is posted. 2024-10-17T08:30:00+09:00 AMYOTROPHIC LATERAL SCLEROSIS TREATMENT “ROZEBALAMIN® FOR INJECTION 25 MG” RECEIVES THE GOOD DESIGN AWARD 2024 FOR LIGHT-PROOF VIAL PACKAGING /news/2024/news202475.html Eisai's news release AMYOTROPHIC LATERAL SCLEROSIS TREATMENT “ROZEBALAMIN® FOR INJECTION 25 MG” RECEIVES THE GOOD DESIGN AWARD 2024 FOR LIGHT-PROOF VIAL PACKAGING is posted. 2024-10-16T14:00:00+09:00 “URECE® TABLETS” (DOTINURAD) APPROVED IN THAILAND FOR GOUT AND HYPERURICEMIA /news/2024/news202474.html Eisai's news release “URECE® TABLETS” (DOTINURAD) APPROVED IN THAILAND FOR GOUT AND HYPERURICEMIA is posted. 2024-10-08T08:30:00+09:00 ӰҵAnnounces Status and Completion of Acquisition of Own Shares /news/2024/news202473.html Eisai's news release ӰҵAnnounces Status and Completion of Acquisition of Own Shares is posted. 2024-10-04T15:35:00+09:00 EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024 /information/2024/pdf/e20241003.pdf Eisai's information EISAI NAMED AS ONE OF NEWSWEEK’S WORLD’S MOST TRUSTWORTHY COMPANIES 2024 is posted. 2024-10-03T15:10:00+09:00 EISAI COMMENCES BUSINESS ACTIVITIES AT NEW PHARMA SALES SUBSIDIARY IN SAUDI ARABIA /news/2024/news202472.html Eisai's news release EISAI COMMENCES BUSINESS ACTIVITIES AT NEW PHARMA SALES SUBSIDIARY IN SAUDI ARABIA is posted. 2024-10-02T08:30:00+09:00 ӰҵAnnounces Status Relating to Acquisition of Own Shares /news/2024/news202471.html Eisai's news release ӰҵAnnounces Status Relating to Acquisition of Own Shares is posted. 2024-10-01T11:30:00+09:00 IR “Annual Securities Report (Summary)” /ir/library/securities/index.html Eisai's latest news IR “Annual Securities Report (Summary)” is posted. 2024-09-30T17:49:35+09:00 ROZEBALAMIN® FOR INJECTION 25 MG (MECOBALAMIN) APPROVED IN JAPAN FOR AMYOTROPHIC LATERAL SCLEROSIS /news/2024/news202469.html Eisai's news release ROZEBALAMIN® FOR INJECTION 25 MG (MECOBALAMIN) APPROVED IN JAPAN FOR AMYOTROPHIC LATERAL SCLEROSIS is posted. 2024-09-24T14:45:00+09:00 ANTICANCER AGENT “TASFYGO® TABLETS 35mg” (TASURGRATINIB SUCCINATE) APPROVED IN JAPAN FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSIONS OR REARRANGEMENTS /news/2024/news202468.html Eisai's news release ANTICANCER AGENT “TASFYGO® TABLETS 35mg” (TASURGRATINIB SUCCINATE) APPROVED IN JAPAN FOR BILIARY TRACT CANCER WITH FGFR2 GENE FUSIONS OR REARRANGEMENTS is posted. 2024-09-24T14:30:00+09:00 RELEASE OF DEMENTIA DISEASE AWARENESS VIDEO FOR WORLD ALZHEIMER’S MONTH “TODAY FOR TOMORROW”: A DOCUMENTARY OF SIX MONTHS FOLLOWING THE CURRENT STATE OF DEMENTIA /news/2024/news202467.html Eisai's news release RELEASE OF DEMENTIA DISEASE AWARENESS VIDEO FOR WORLD ALZHEIMER’S MONTH “TODAY FOR TOMORROW”: A DOCUMENTARY OF SIX MONTHS FOLLOWING THE CURRENT STATE OF DEMENTIA is posted. 2024-09-17T10:00:00+09:00 LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma /news/2024/news202466.html Eisai's news release LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma is posted. 2024-09-17T08:30:00+09:00 Investigator-initiated clinical studies to be launched following confirmation of tumor shrinkage induced by the targeted protein degrader E7820 using J-PDX (Japanese cancer patient-derived tissue transplantation models) /news/2024/news202465.html Eisai's news release Investigator-initiated clinical studies to be launched following confirmation of tumor shrinkage induced by the targeted protein degrader E7820 using J-PDX (Japanese cancer patient-derived tissue transplantation models) is posted. 2024-09-12T16:07:24+09:00 EISAI ACCELERATES PROGRESS IN ONCOLOGY RESEARCH WITH NEW DATA AT ESMO CONGRESS 2024 /news/2024/news202464.html Eisai's news release EISAI ACCELERATES PROGRESS IN ONCOLOGY RESEARCH WITH NEW DATA AT ESMO CONGRESS 2024 is posted. 2024-09-05T08:30:00+09:00